logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Pharmaceutical companies reaffirm their commitment to research and access to innovation in Spain

Predictability, adequate taxation and imagination in the search for solutions, within the framework of a constant dialogue with the Administration, keys to ensure the advancement of biomedical R&D in Spain

Responsible for MSD, Roche, Amgen and Rovi Laboratories participated in a round table at the XIX Meeting of the Spanish Pharmaceutical Industry in Santander

 

Source: www.farmaindustria.es

Representatives of different pharmaceutical companies participating in the XIX Meeting of the Spanish Pharmaceutical Industry, held on September 5 and 6 in Santander, reaffirmed the commitment of laboratories to research, and especially to clinical research, in Spain, a country that it is already for many companies that attracts more investments in clinical trials after the United States.

At the same time, those responsible for MSD, Roche, Amgen and Rovi Laboratories, who participated in a round table under the title The contribution of pharmaceutical companies to research in Spain: where are we and how to progress ?, highlighted the importance to achieve greater efficiency in the evaluation processes of new medicines to optimize patients’ access to innovation in Spain.

Both the president of MSD Spain, Ana Argelich, and the director of Institutional Relations of Roche Spain, Federico Plaza, highlighted the importance that Spain has gained in recent years as a destination for investments in biomedical R&D, and in particular in clinical research .

In this sense, Argelich considered that there is continuity and an impulse that reinforces public-private partnerships, as well as a recognition of R&D and innovation as strategic engines of growth. In addition, he advocated continuing work to improve equity in access in Spain and to take into account the health results of innovation.

Plaza said that Spain has managed to place itself in the advance by implementing the new designs of clinical trials (such as the so-called basket and umbrella), aimed at patients who share the same genetic mutation even if they do not necessarily have the same type of cancer or the same organ affected . For the representative of Roche Spain, the existence of a high quality research fabric and the stability environment have been key factors in attracting investments in biomedical R&D to Spain.

A regulation favorable to innovation

This commitment to advance research through innovative clinical trial designs was also highlighted by Amgen Spain’s general director, Fina Lladós, who underlined the great training of Spanish healthcare professionals and researchers as a key to making Spain an attractive country for Invest in biomedical R&D. In this context it is crucial, according to Lladós, that the Government and the institutions make possible a regulation that facilitates innovation, since research does not make sense if patients cannot benefit from it.

Juan López-Belmonte, CEO of Laboratorios Rovi, contributed the optics of the pharmaceutical industry of Spanish capital, and emphasized the importance of incremental innovation, which improves or finds new uses for existing medicines, which allows for more solutions to doctors and patients. He also recalled that this type of innovation, accumulated over time, also ends up becoming disruptive innovation, and stressed the importance that it has, for national capital companies, to position themselves solidly in the niches that allow them provide more value, both nationally and internationally.

In any case, the representatives of the companies agreed to highlight how predictability, adequate taxation and imagination in the search for solutions, within the framework of a constant dialogue with the Administration, are key to ensuring the progress of R&D Biomedical in Spain. Thus, they insisted on everyone’s responsibility so that the medicine reaches each patient who needs it and proposed to better measure the real value that innovative drugs provide, collaborating with the Administration in its financing.

Distefar supports a regulation that is consistent and favorable to innovative research in clinical trials. In this way, Spain is the second country to attract this type of investment, only behind the United States.

Related entries

4 October, 2023

“Artificial intelligence and technology are driving digital therapies, which benefit not only patients, but the healthcare system and society as a whole”.


Leer más
2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más

Recent Posts

  • “Artificial intelligence and technology are driving digital therapies, which benefit not only patients, but the healthcare system and society as a whole”.
  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.